Abstract Taurine (2-aminoethanesulfonic acid) is a potent antioxidant and inhibits cell apoptosis in ischemic reperfusion injury. In this study we evaluated whether addition of taurine to St. Thomas' cardioplegic solution enhances its myocardial protective effects in prolonged hypothermic heart preservation in rats. Hearts isolated from male Sprague-Dawley rats were mounted on a Langendorff apparatus to estimate baseline cardiac function, then arrested and stored in St. Thomas' cardioplegic solution, with taurine (10 mM; taurine group, n = 8) or without taurine (control group, n = 8), for 6 h at 4°C. After storage, the hearts were reperfused and heart rate (HR), coronary flow (CF), left ventricular developed pressure (LVP), and positive maximum left ventricular developing pressure (max LV dp/dt) were measured. The LV tissue was examined immunohistochemically for determining DNA oxidative stress and cell apoptosis. Compared with control groups, recovery of LVP (P < 0.001), max LV dp/dt (P < 0.001), and coronary flow (P < 0.001) were significantly enhanced, whereas glutamic oxaloacetic transaminase (P < 0.01), lactate dehydrogenase (P < 0.05), creatine phosphate kinase (P < 0.01), 8-hydroxy-2¢-deoxyguanosine index (P < 0.01), caspase-3 mRNA expression (P < 0.05), and percentage of TUNEL-positive cardiomyocytes (P < 0.05) were reduced in the taurine group. Addition of taurine to St. Thomas' cardioplegic solution improved cardiac function recovery for prolonged hypothermic rat heart preservation by suppressing DNA oxidative stress and cell apoptosis.
Introduction
One of the major limitations of heart transplantation has been the effective preservation of the donor heart. Currently used preservation solutions offer only up to 4 h of safe storage. 1 Because heart transplantation survival correlates inversely with cold ischemic time, improvement in the quality of the preservation solution is needed.
The heart loses a considerable part of its functions due to ischemia and reperfusion (I/R) injury, in which the generation of reactive oxygen species (ROS) is thought to have a critical role. 2 Reactive oxygen species lead to lipid peroxidation and protein oxidation, and cause cell death via apoptosis. The severity of cardiomyocyte damage correlates positively with the duration of I/R. 3, 4 Taurine (2-aminoethanesulfonic acid) is the most abundant free amino acid in mammalian tissues. It makes up more than 50% of the total free amino acid pool in the heart, with an intracellular concentration of about 6-35 mM. In the myocardium, it produces a positive inotropic effect and has beneficial effects for the treatment of congestive heart failure. Taurine also exerts cytoprotective properties such as antioxidation, antiapoptosis, osmoregulation, membrane stabilization, and intracellular calcium flux regulation. 5 That taurine protects the heart from I/R injury was demonstrated in cultured cardiomyocytes and in short-term isolated heart perfusion. 6, 7 It also facilitates the functional recovery of solid organs, such as liver and kidney, after ischemic hypothermic storage. [8] [9] [10] [11] In the present study, we tested the hypothesis that the addition of taurine to St. Thomas' cardioplegic solution would improve its efficacy for prolonged hypothermic heart preservation.
Materials and methods

Animals
We used adult male Sprague-Dawley rats (350-450 g body weight). All animals received humane care in compliance with the Principles of Laboratory Animal Care formulated by the National Society for Medical Research and the Guide for the Care and Use of Laboratory Animals prepared by the Institute of Laboratory Animal Resources and published by the National Institutes of Health.
Isolated heart perfusion
The experimental protocol is shown in Fig. 1 . Rats were anesthetized with pentobarbital (50 mg/kg) intraperitoneally and heparinized (1000 IU/kg, intravenous). After 5 min of anesthesia, the hearts were rapidly excised from the chest and were mounted onto the nonworking type of Langendorff perfusion system, and retrogradely perfused via the aorta with normothermic 37.5°C Krebs-Henseleit buffer at the constant pressure of 100 cmH 2 O, saturated with 95% O 2 and 5% CO 2 . After 20 min perfusion, the heart was arrested with an aorta injection of 4 ml of 4°C commercially available St. Thomas' cardioplegic solution with taurine (10 mM; Sigma-WAKO, Tokyo, Japan) (taurine group, n = 8) or without taurine (control group, n = 8), then stored in 40 ml of the same solution at 4°C. After 6 h of storage, hearts were remounted on the Langendorff apparatus and reperfused for 40 min with Krebs-Henseleit buffer. The composition of Solutions used are given in Table 1 .
Evaluation of left ventricular function
To measure left ventricular pressure, a latex balloon was inserted through the left atrium into the left ventricular cavity and connected via a fluid-filled polyethylene tube to a pressure transducer. The balloon pressure was then adjusted to 10 mmHg of the left ventricular end-diastolic pressure. Heart rate, left ventricular developed pressure (LVP), positive maximum rate of left ventricular developing pressure (max LV dp/dt, mmHg/s), and coronary flow were measured before ischemia and after reperfusion (Fig. 1) . Coronary flow was measured by collecting the coronary effluent buffer at the same time points as above.
Measurement of cardiac enzymes
The extent of release of cardiac enzymes was measured from samples of the coronary effluent buffer. Creatine   Fig. 1A,B Units are mmol/l except when indicated
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phosphate kinase (CPK), glutamic oxaloacetic transaminase (GOT), and lactic dehydrogenase (LDH) were measured using an AU5200 autoanalyzer (Olympus, Tokyo, Japan). Enzyme activities were expressed in units per minute (IU).
Immunohistochemical assay of 8-hydroxy-2¢-deoxyguanosine 8-Hydroxy-2¢-deoxyguanosine (8-OHdG) is one of the major products of oxidative DNA modifications. 12 To analyze 8-OHdG, which is an established marker for DNA damage, [13] [14] [15] we used the alkaline-phosphatase technique. After deparaffinization, either primary antibody (Japan Institute for the Control of Aging, Fukuroi, Shizuoka, Japan) or normal mouse serum was added and incubated overnight. Biotin-labeled rabbit antimouse IgG (Dako) was used as the second antibody for 40 min, followed by an avidin-biotin-alkaline phosphatase complex (Vector). Counterstaining was not performed. The level of 8-OHdG (8-OHdG index) was measured and quantitated as follows 16 :
8-OHdG index threshold area pixels total cell number
where X is the staining density indicated in gray scale, using the NIH image Detection of apoptotic cardiomyocytes A TUNEL assay was performed for detection of apoptotic cells using a commercial kit (apoptosis in situ detection kit; Wako, Osaka, Japan) according to the manufacturer's instructions. Digoxigenin-labeled dUTP was catalytically incorporated into the DNA by terminal deoxynucleotidyl transferase, an enzyme that catalyzes a template-independent addition of nucleotide triphosphate to the 3¢-OH ends of double-or single-strand DNA.
Analysis of mRNA expression
Total mRNA was prepared from the left ventricular pieces by use of TRIzol (Life Technologies, Gaithersburg, MD, USA), and reverse-transcribed and amplified with an ABI Prism 7700 Sequence Detector (Applied Biosystems, Foster City, CA, USA). Polymerase chain reaction (PCR) conditions were 40 cycles of denaturing at 94°C for 20 s and primer annealing/extension at 62°C for 60 s. The nucleotide sequences of PCR primers and TaqMan probes were follows: caspase-3, forward primer: 5¢-AATTCAA GGGACGGGTCATG-3¢, reverse primer: 5¢-GCTTGT GCGCGTACAGTTTC-3¢; TaqMan probe: 5¢-TTCAT CCAGTCACTTTGCGCCATG-3¢. The TaqMan rodent glyceraldehyde-3-phosphate dehydrogenase (GAPDH) control reagents were used to detect rat GAPDH as the internal standard. The expression levels of target gene were normalized by the GAPDH level in each sample.
Statistical analysis
Statistical analysis was performed with Statview software (ver. 5.0; SAS Institute, Cary, NC, USA). All data are expressed as mean ± SEM. For comparison between two groups, significance was determined by the Student t-test. For comparison among multiple groups, analysis of variance and a Fisher post hoc test analysis was used. A value of P < 0.05 was considered significant.
Results
Recovery of cardiac function
There was no significant difference between the two groups at baseline (Table 2) . After 6 h storage followed by 40 min reperfusion, heart rate was recovered to preischemic levels in both of the groups. However, in the taurine group, cardiac function recovery of LVP (P < 0.001) and max LV dp/ dt (P < 0.001) was considerably greater than in the control groups. In addition, max LV dp/dt reached 91.6% of preischemic values when the control group recovered 67% of preischemic values. Moreover, coronary flow was recovered better in the taurine group than in the control group (P < 0.01) ( Fig. 2A-D) .
Release of cardiac enzymes
Taurine decreased the release of CPK (P < 0.01), LDH (P < 0.05), and GOT (P < 0.01) after 6 h storage followed by 40 min reperfusion, these effects being significant compared with the control group (Fig. 3A-C ).
Oxidative stress on DNA
We carried out immunohistochemistical analysis of 8-OHdG levels to evaluate the oxidative stress on DNA in the Data are shown as mean ± SEM. There were no significant differences in any variables dp/dt, left ventricular developing pressure; GOT, glutamic oxaloacetic transaminase; LDH, lactate dehydrogenase; CPK, creatine phosphate kinase Fig. 2A-C . Recovery of cardiac function. A There were no significant differences between the two groups in heart rate before and after 6 h storage followed by 40 min reperfusion. B, C The taurine group showed a significantly greater left ventricular developed pressure (LVP) (***P < 0.001), maximum rate of left ventricular developing pressure (max LV dp/dt) (***P < 0.001), and coronary flow (**P < 0.01) than the control group after 6 h storage followed by 40 In both of the taurine and control groups, clear nuclear staining of cardiomyocytes was observed in the left ventricular tissues after 6 h storage followed by 40 min reperfusion. The staining was apparently more prominent in the control group (Fig. 4A,B) . The 8-OHdG index calculated from staining in the control group (63.8 ± 2.0) was significantly higher than the index in the taurine group (38.0 ± 3.8, P < 0.001) (Fig. 4C) .
Evaluation of myocardial apoptosis
To evaluate the degree of myocardial apoptosis, we evaluate TUNEL staining and the expression of caspase-3 mRNA. A significantly decrease in TUNEL-positive cells was observed in the taurine group hearts compared with the control group hearts (Fig. 5A ,B) after 6 h storage followed by 40 min reperfusion. The percentage of TUNEL-positive cells (P < 0.05) and caspase-3 mRNA expression (P < 0.05) was significantly diminished in the taurine group compared with the control group after 6 h storage followed by 40 min reperfusion (Fig. 5C,D) . In the taurine group a lesser amount of nuclear oxidative DNA damage occurred than in the control group. Note that the cell nuclei are stained dark (¥400). C Quantification of oxidative stress on DNA. The 8-OHdG index calculated from staining in the control group was significantly higher than the index in the taurine group (*P < 0.01). All values are expressed as mean ± SEM
Discussion
In the present study, we have shown that the addition of taurine to St. Thomas' cardioplegic solution significantly improved cardiac function recovery, reduced release of cardiac enzymes, and markedly diminshed immunohistochemiclly stained oxidative DNA and cell apopotosis. These results are consistent with previous studies, which demonstrated that taurine attenuates I/R injury by suppressing oxidative stress and apoptosis. 6, [17] [18] [19] Taurine (2-aminoethanesulfonic acid) is the most abundant free amino acid in mammalian tissues. It makes up more than 50% of the total free amino acid pool in the heart, with an intracellular concentration of about 6-35 mM. In cat and rat, pharmacologically induced taurine deficiency leads to dilative cardiomyopathy. [20] [21] [22] A clinical, worldwide multicenter WHO-CARDIAC study reported a strong and inverse association between population levels of taurine excretion and ischemic heart disease mortality. 23 Taurine has been used to treat patients with congestive heart failure, and preoperative intravenous infusion of taurine reduced reperfusion injury during coronary artery C Fig. 5 . A,B TUNEL staining of the myocardium. Apoptosis was suppressed in the taurine group compared with that in the control group (arrow heads: TUNEL-positive cell) (¥200). C The percentage of TUNEL-positive cardiomyocytes in the taurine group was significantly diminished compared with the control group (*P < 0.05). D Expression of caspase-3 mRNA. Caspase-3 mRNA expression was significantly decreased in the taurine group hearts compared with the control group hearts (*P < 0.05). All values are expressed as mean ± SEM. GAPDH, glyceraldehyde-3-phosphate dehydrogenase bypass grafting surgery. 24, 25 That taurine protects the heart from I/R injury was demonstrated in cultured cardiomyocytes and in short-term isolated heart perfusion. 6, 7 In the current study, the data showed that taurine supplementation reduced I/R injury, evidenced by improving cardiac function (LVP, LV dp/dt, coronary flow) (Fig. 2) and reducing CPK, LDH, and GOT release (Fig. 3) . The mechanism of the attenuation of I/R injury by taurine is still not fully understood, but at least three possibilities have been proposed. (1) Taurine supplementation prevents a large amount of taurine loss from the cell and maintains an extracellularly high concentration of taurine during prolonged hypothermic rat heart preservation. (2) Taurine can act as a direct antioxidant by scavenging ROS and as an indirect antioxidant by preventing changes in membrane permeability due to oxidant stress. [33] [34] [35] [36] [37] [38] [39] (3) Taurine prevents I/R-induced cardiomyocyte apoptosis by inhibiting the activation of caspase-3. 45 Normally the myocardial taurine content is stable, but a large amount of taurine is rapidly lost from the cardiomyocytes during I/R. Schaffer et al. noted that 1.6 mM/min of taurine was released into the coronary effluent from rat hearts after an ischemic insult of 45 min. 26 Crass and Lombardini reported that cardiac muscle taurine reduced 47% in the left ventricle and 26% in right and left atria after 4 h occlusion of the circumflex branch of the left coronary artery in dog. 27 Harada et al. reported that oral taurine supplementation increased myocardial taurine levels by over 50%. 28 Oudit et al. reported that taurine supplementation improved cardiac function and blood pressure in ironoverloaded mice. 29 Also, Takahashi et al. reported that addition of taurine to the medium during the ischemic insult not only prevented the decline in taurine content but actually elevated taurine levels by about 9-10 times after 24 h ischemia. 6 In the present study we did not measure the content of taurine in the cardiomyocytes, but from data in previous reports 6, 28, 29 we believe that taurine supplementation prevents taurine loss and maintains a high extracellular concentration of taurine during prolonged hyporthermic rat heart preservation. This may contribute toward preventing taurine deficiency-related I/R injury and decreasing cardiac function recovery.
Ischemia/reperfusion results in the generation of toxic ROS in the myocardium. Ischemia reduces the activity of C D cellular defense enzymes against ROS, and reperfusion or introduction of oxygen further disturbs the delicate balance of oxidants/antioxidants, generating a burst of ROS. [30] [31] [32] Reactive oxygen species lead to lipid peroxidation and protein oxidation, causing cell death via apoptosis and ROS-mediated myocardial dysfunction. The volume of generation of ROS and severity of cardiomyocyte damage correlates positively with the duration of I/R. [2] [3] [4] 31 Taurine is a potent antioxidant and prevents tissue injury, mainly through antioxidation. 8-OHdG, one of the major products of oxidative DNA modifications, was measured as a marker of oxidative stress. Previous studies have demonstrated that 8-OHdG levels were increased in cardiomyocytes after myocardial infarction. 14, 15, 33 In the present study, by calculating the 8-OHdG index, we demonstrated the ability of taurine to protect DNA against oxidative stress during prolonged hypothermic rat heart preservation ( Fig. 4A-C) . The following mechanism has been proposed for the antioxidant effects of taurine. (1) As a direct antioxidant, taurine can quench and detoxify some reactive intermediates such as hypochlorous acid generated by myeloperoxidase, 34 ,35 nitric oxide, 36 and H 2 O 2 . 37 (2) As an indirect antioxidant, taurine may protect cells by intercalating into the membrane and stabilizing it. 35, 38 Taurine was reported to be beneficial in preventing lead-induced oxidative damage, 39 CCl 4 -induced oxidative stress, 40 caerulein-induced acute pancreatitis, 41 and early changes in experimental diabetic kidney 42 through antioxidant mechanisms. Apoptosis is the dominant form of cardiomyocyte death during I/R, 43 and the number of apoptotic cells is negatively correlated with cardiac function. 44 Because of the loss of proliferative ability of cardiomyocytes, cell loss will result in a decrease in the number of contractile units, and this will eventually cause pump failure directly. Therefore, the possibility of limiting cardiomyocyte loss by inhibiting apoptosis has potentially important implications in the treatment of cardiac dysfunction. One of the factors that regulate the degree of apoptosis during I/R is amino acid taurine. 17 TUNEL staining is commonly used for detection of apoptosis. Caspase-3, which is one of the interleukinconverting enzyme families of cysteine protease, is known to mediate apoptosis in cardiomyocytes. The process of apoptosis has many pathways, but caspase-3 is thought to be central to the apoptotic pathway. 45 Takatani et al. demonstrated that taurine treatment had no effect on mitochondrial membrane potential and cytochrome c release; it inhibits the activation of caspase-9 and caspase-3 in ischemic cardiomyocytes. 17 The effector caspase, caspase-3, is activated through cleavage by the initiator caspase-9. Therefore, caspase-3 activity can be used as a molecular marker of myocardial apoptosis. The present study showed a significant decrease in TUNEL-positive cells (Fig. 5A,B) and expression of caspase-3 mRNA (Fig. 5C ) in the taurine group compared with the control group. These results are consistent with the former mechanism, that is, taurine may have blocked the apoptosis pathway via caspase-3 during I/ R. 17 Our data showed about 7% of apoptotic-positive cells and 67% max LV dp/dt recovery in the control group hearts after prolonged hyporthermic heart preservation. By contrast, only about 2% of apoptotic-positive cells and 91.6% max LV dp/dt recovery occurred in the taurine group hearts after prolonged hyporthermic heart preservation. Takahashi et al. reported that ischemia significantly increased the number of apoptotic cells, with the extent of apoptosis being 21%-45% during 48-72 h of ischemia, but myocytes treated with taurine were resistant to ischemiainduced apoptosis, as only 16%-23% of the cells underwent apoptosis during the 48-72-h ischemic insult. 6 These beneficial effects of taurine are suggested to contribute to attenuation of I/R injury and improvement of cardiac function recovery in prolonged hypothermic heart preservation. Also, inhibition of apoptosis by taurine was reported in iron-overload-induced apoptosis of cardiomyocytes, 29 highglucose-induced human vascular endothelial cell apoptosis, 18 and ischemia-induced apoptosis in cultured neonatal rat cardiomyocytes. 6 A previous study by Franconi et al. reported that taurine, when administered as a pharmacological tool in various animal models, was generally used in a range from 10 to 30 mM. 46 They reported that 10 and 20 mM taurine concentrations are capable of reducing cardiac enzyme release and improving cardiac function. 7 In another study, it was demonstrated that the addition of taurine (10 mM) to a crystalloid preservation solution improved hepatic circulation and enhanced viability of the graft liver. 10 In view of these findings, we used taurine at a concentration of 10 mM for the protection of myocytes against I/R injury.
A limitation of our study is that we used only St. Thomas' cardioplegic solution to test the myocardial protective effect of taurine and did not examine its effect on other preservation solutions. Regarding the several preservation solutions, each has a different protective effect in different organs. Each institution selects and uses the best solution according to basic data and clinical experience. Therefore, further studies are required to examine the cardioprotective effect of taurine with the best preservation solution. In this study, the crystalloid-perfused Langendorff preparation was used because it allows for analysis of interventions of the isolated heart without humoral, neural, adrenergic, or anesthetic influences. However, to extrapolate our findings to clinical applications, a study of large animal transplantation models will be necessary.
In conclusion, our study using Langendorff perfused isolated rat hearts demonstrated that addition of taurine to St. Thomas' cardioplegic solution effectively preserved left ventricular cardiac function and reduced cardiomyocyte injury by suppressing DNA oxidative stress and apoptosis, in prolonged hypothermic rat heart preservation. It is therefore reasonable to infer that taurine has potential significance for clinical application in heart transplantation surgery.
